Opinion|Videos|October 14, 2024
Interpreting DeLLphi-301 Trial Results: ORR, Duration of Response, and Long-Term Outcomes
Author(s)Joshua K. Sabari, MD
Joshua K. Sabari, MD, discusses how the ORR of 32% to 40% observed in the DeLLphi-301 clinical trial among participants receiving tarlatamab is clinically meaningful, particularly given that these responses occurred between 5 and 7 weeks after initiation and emphasize the importance of ORR as a primary end point in evaluating the efficacy of treatment in this patient population.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Please provide your insights on an ORR of 32% to 40% among participants in the 10-mg and 100-mg groups of the DeLLphi-301 clinical trial.
- How clinically meaningful is an objective response observed between 5 and 7 weeks of tarlatamab initiation?
- Please express your views on selecting ORR as the primary end point in this study.
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.
Pan-cancer study shows age-based germline testing misses most inherited cancer variants, supporting broader genetic screening to guide treatment and family risk.
The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival with standard of care in glioblastoma but showed benefit in patients aged 65 and below.
The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on median PFS of 24.9 vs 16.3 months in HER2CLIMB-05.
Daznelimgene lisbac (OST-HER2) moves toward FDA submission based on comparison to historical control; brand name accepted by WHO.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer
2
Costa Explains What Drives Survival Benefit With Tec/Dara in Myeloma
3
c-Met ADC Temab-A Gains 2 FDA Breakthrough Designations in CRC, NSCLC
4
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
5